Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Clin Infect Dis ; 59(2): 244-51, 2014 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-24759830

RESUMEN

BACKGROUND: About 10% of pediatric patients with invasive pneumococcal disease (IPD) die from the disease. Some primary immunodeficiencies (PIDs) are known to confer predisposition to IPD. However, a systematic search for these PIDs has never been carried out in children presenting with IPD. METHODS: We prospectively identified pediatric cases of IPD requiring hospitalization between 2005 and 2011 in 28 pediatric wards throughout France. IPD was defined as a positive pneumococcal culture, polymerase chain reaction result, and/or soluble antigen detection at a normally sterile site. The immunological assessment included abdominal ultrasound, whole-blood counts and smears, determinations of plasma immunoglobulin and complement levels, and the evaluation of proinflammatory cytokines. RESULTS: We included 163 children with IPD (male-to-female ratio, 1.3; median age, 13 months). Seventeen children had recurrent IPD. Meningitis was the most frequent type of infection (87%); other infections included pleuropneumonitis, isolated bloodstream infection, osteomyelitis, endocarditis, and mastoiditis. One patient with recurrent meningitis had a congenital cerebrospinal fluid fistula. The results of immunological explorations were abnormal in 26 children (16%), and a PID was identified in 17 patients (10%), including 1 case of MyD88 deficiency, 3 of complement fraction C2 or C3 deficiencies, 1 of isolated congenital asplenia, and 2 of Bruton disease (X-linked agammaglobulinemia). The proportion of PIDs was much higher in children aged >2 years than in younger children (26% vs 3%; P < .001). CONCLUSIONS: Children with IPD should undergo immunological investigations, particularly those aged >2 years, as PIDs may be discovered in up to 26% of cases.


Asunto(s)
Síndromes de Inmunodeficiencia/complicaciones , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/inmunología , Adolescente , Niño , Preescolar , Susceptibilidad a Enfermedades , Femenino , Francia , Humanos , Lactante , Masculino , Estudios Prospectivos
3.
Front Pediatr ; 10: 1000657, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36507149

RESUMEN

Background: In Europe, meningococcal (Men) vaccines are available against 5 of the 6 serogroups responsible of nearly all cases of invasive meningococcal disease (IMD). Meningococcal vaccination has been introduced in the national immunization programs (NIPs) for children and adolescents of numerous European countries, but with no consistent strategy across countries. Objectives: To describe IMD epidemiology, NIPs, and vaccination coverage rates (VCRs) in children and adolescents in 8 Western European countries. Methods: Epidemiological data (from 1999 to 2019), NIPs regarding meningococcal vaccination status, and VCRs were collected from the European Centre for Disease Prevention and Control (ECDC) and/or national websites. Results: MenB was the most common serogroup. In Belgium, Spain, France, the Netherlands, the United Kingdom (UK), and Portugal, incidence was greater for MenW than MenC. In 2019, MenB risk was covered in 2 countries (Italy, UK). MenC risk was covered in all countries, via MenC only (countries: N = 3), MenACWY only (N = 2), or MenC (infants/children) and MenACWY (adolescents) (N = 3) vaccination. VCRs were higher in children than adolescents. Conclusion: Our study confirmed the diversity of NIPs, including in neighboring European countries with similar factors like economic resources and epidemiological risk, thus indicating that other factors underlie NIPs. Convergence toward a more common immunization program including MenACWY and MenB vaccination would promote equity and safe travel regarding infectious diseases for young people, and possibly improve the understanding of vaccination by patients and healthcare professionals.

4.
Ann Biol Clin (Paris) ; 69(4): 481-4, 2011.
Artículo en Francés | MEDLINE | ID: mdl-21896417

RESUMEN

An 11 year old African boy without previous history was hospitalised for fever and a severe anaemia (haemoglobin = 55 g/L) with low reticulocyte count. Blood smear showed more than 35% of ghost red blood cells which allows the diagnosis of G6PD deficiency (< 1% of normal level). Anaemia was demonstrated as haemolytic and was associated with a drepanocytosis trait. Aspect of red blood cells on blood smear remains important for the diagnosis of congenital or acquired red blood cell diseases, even abnormalities are often of low specificity.


Asunto(s)
Eritrocitos/patología , Deficiencia de Glucosafosfato Deshidrogenasa/diagnóstico , Anemia Aplásica/diagnóstico , Niño , Diagnóstico Diferencial , Recuento de Eritrocitos , Deficiencia de Glucosafosfato Deshidrogenasa/patología , Humanos , Masculino
5.
Eur J Pediatr ; 169(10): 1293-7, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20461528

RESUMEN

Chickenpox is often considered more severe during the first year of life, but its course is usually mild during the first 3 months of life, presumably owing to the persistence of maternal antibodies. Hospitalization and intravenous acyclovir therapy are generally restricted to severe cases but also systematically recommended in newborns in France, irrespective of the clinical severity of the infection. This recommendation was launched in 1998 when Varicella zoster virus (VZV)-specific immunoglobulins were not available in the country and has remained unchanged since. The aim of this prospective observational study was to describe complications of varicella infection in a population of 745 children hospitalized for varicella before 1 year of age, with a specific focus on newborns. Complications occurred in 65% of cases. They were very rare before the age of 1 month (10%) but their incidence then increased progressively with age and probably the disappearance of maternal antibodies: 42% (1-2 months), 66% (3-5 months), 70% (6-8 months), and 79% (9-12 months). Conclusion Chickenpox is usually mild in newborns because most of them are protected by VZV maternal antibodies. Unless the absence of maternal VZV immunity is demonstrated, newborns with mild chickenpox should not require antiviral therapy.


Asunto(s)
Varicela/epidemiología , Hospitalización/estadística & datos numéricos , Distribución de Chi-Cuadrado , Varicela/complicaciones , Femenino , Francia/epidemiología , Humanos , Lactante , Recién Nacido , Masculino , Estudios Prospectivos , Factores de Riesgo
6.
Eur J Pediatr ; 169(12): 1561-3, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20661589

RESUMEN

Inherited metabolic disorders are the cause of a small but significant number of sudden infant deaths in infants. We report on a boy who suddenly died at 10 months of age during an acute illness. Parents declined autopsy; nevertheless, they accepted a whole body MRI, which revealed hepatomegaly with steatosis. Acylcarnitine profile of a blood sample from neonatal Guthrie screening led to the diagnosis of type 2 carnitine palmitoyltransferase deficiency. To conclude, whole body MRI is useful in the investigation of some inherited metabolic causes of sudden infant death, which might prevent future deaths in the family. It is a good alternative when autopsy is refused.


Asunto(s)
Carnitina/análogos & derivados , Hepatomegalia/patología , Imagen por Resonancia Magnética , Muerte Súbita del Lactante/diagnóstico , Muerte Súbita del Lactante/etiología , Carnitina/sangre , Carnitina O-Palmitoiltransferasa/deficiencia , Causas de Muerte , Diagnóstico , Hígado Graso/patología , Humanos , Lactante , Masculino , Errores Innatos del Metabolismo/complicaciones , Errores Innatos del Metabolismo/diagnóstico , Errores Innatos del Metabolismo/patología , Cambios Post Mortem , Muerte Súbita del Lactante/patología
7.
Rev Prat ; 60(10): 1373-6, 2010 Dec 20.
Artículo en Francés | MEDLINE | ID: mdl-21425531

RESUMEN

Vaccine coverage against hepatitis B has really increased in French infants since march 2008, date of reimbursement of hexavalent vaccine. At the end of year 2009, 76% of infants have received at least one dosage of hepatitis B vaccine before the age of 6 months. On the contrary until the beginning of year 2008 only 30 to 40% have been vaccinated. Altogether with the reimbursement we have to take into account, knowledge of French epidemiological data, 280000 chronic carrier of hepatitis, whom half of them does not know her state and 1 300 deaths each year, and a change in the opinion by physicians and families. If this result can be considered as good, vaccine coverage of adolescents is not good, about 50% and need to be increased. All non vaccinated adolescent would have the opportunity to be vaccinated. Adolescent can be vaccinated between 11 and 15 years old with a 3 dosages schedule (0, 1, 6 months) or a 2 dosages schedule (0,6 months) with vaccines which contain 20 microgrammes Ag HBs.


Asunto(s)
Vacunas contra Hepatitis B , Hepatitis B/epidemiología , Hepatitis B/inmunología , Francia/epidemiología , Política de Salud , Hepatitis B/prevención & control , Humanos , Programas de Inmunización
8.
Rev Prat ; 60(10): 1380-5, 2010 Dec 20.
Artículo en Francés | MEDLINE | ID: mdl-21425533

RESUMEN

Three years after the generalization of the recommendation of Pneumococcal conjugate vaccine for all infants under two years of age, the rate of vaccine coverage is satisfactory for the primovaccination (above 85%) with a 2 + 1 schedule. Vaccine coverage is too low for the booster which is given too late (at 14,5 months of age) and not at of 12 months. This conjugate vaccine has a direct effect, due to the vaccine in the target population and indirect effect due to the action on the strains carriage which decreases the broadcasting of the vaccine serotype strains and protect non vaccinated populations. In 2007, invasive pneumococcal diseases (meningitis and bacteremia) have decreased about 3% in infants under two years of age but globally, the incidence of invasive pneumococcal disease has not been modified. There is a substitution for strains and a change in the serotypes distribution with a prominence of 19A and 7 F and 1 serotype. Added to the benefit on invasive pneumococcal diseases, there are others on pneumonia, otitis media and antibiotic resistance of pneumococcus. Six serotypes have been added to obtain the Prevenar 13 which replaces the seven valent vaccine. Prevenar 13 has the same recommendations as Prevenar and can be given by the same schedule 2 + 1 (2 months, 4 months, and 12 months) except in high risk children and premature newborns who have to be vaccinated by a 3 + 1 schedule. Epidemological surveillance of the strains has to be done, As for adults, the data are currently being analyzed.


Asunto(s)
Vacunas Neumococicas , Streptococcus pneumoniae/inmunología , Francia/epidemiología , Humanos , Esquemas de Inmunización , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/prevención & control , Factores de Riesgo , Vacunas Conjugadas
9.
Rev Prat ; 60(10): 1363-7, 2010 Dec 20.
Artículo en Francés | MEDLINE | ID: mdl-21425528

RESUMEN

Preventive vaccination strategy around the birth is a global approach requiring the coordination of several actors. To be efficacious, general practitioners are in the front line to provide preventive care and health education. The perinatal period represents a privileged situation from listening to this approach of vaccine prevention. The raising awareness around the birth contains several additional steps to bring to the future mother and child the best protection against infectious diseases with vaccine prevention. By being vaccinated, parents and other family members indirectly provide protection to very young infants until they are old enough to be vaccinated and so directly protected themselves. Numerous opportunities exist to make sensitive the parents in this preventive way, for them and their child, whether it is from the adolescence in the adulthood above all parental project, on the occasion of a pregnancy, at birth, during the stay in maternity hospital, or along the first weeks of the postpartum. The general practitioner is the key actor to coordinate this global approach in perinatal health around the mother, his child and his family. The arrival of the newborn will be the opportunity to update vaccinations of the whole family particularly according chicken pox, measles, rubella, whooping cough and flu vaccines.


Asunto(s)
Enfermedades del Recién Nacido/prevención & control , Atención Perinatal , Complicaciones Infecciosas del Embarazo/prevención & control , Vacunación , Femenino , Humanos , Recién Nacido , Embarazo
10.
Hum Vaccin Immunother ; 16(10): 2518-2523, 2020 10 02.
Artículo en Inglés | MEDLINE | ID: mdl-32209010

RESUMEN

In France, the incidence of invasive meningococcal disease (IMD) is around 1/100,000, with the following trends over the 2011-2018 period: a leading role of group B in subjects <15 years, a decrease of group C among <1 year since 2017, an increase of group W in all age groups including subjects <1 year since 2014 and a positive correlation between group Y and age group. In Europe, vaccination progressed with conjugate ACWY vaccines and proteins-based B vaccines. Their benefit-risk-cost balance is however not so obvious for area at low incidence (<2/100,000), explaining tremendous variations between countries, from no recommendation to recommend all available vaccines. In France, the calendar still includes only C with a good adhesion in infants but a fiasco of the catch-up campaign in adolescents and young adults. In Europe, it is time to consider not only national epidemiology but also trends in the neighborhood. The increase of group W cases encourages switching C to ACWY vaccine both in infants and adolescents. It is also time to protect infants with B vaccine. Large pedagogy on the disease is required to increase the adhesion to the vaccination and to recognize and treat earlier the residual cases.


Asunto(s)
Infecciones Meningocócicas , Vacunas Meningococicas , Neisseria meningitidis , Adolescente , Europa (Continente)/epidemiología , Francia/epidemiología , Humanos , Incidencia , Lactante , Infecciones Meningocócicas/epidemiología , Infecciones Meningocócicas/prevención & control , Vacunación , Vacunas Conjugadas , Adulto Joven
11.
Front Immunol ; 11: 595478, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33250898

RESUMEN

Primary infection with varicella-zoster virus (VZV) causes chickenpox, a benign and self-limited disease in healthy children. In patients with primary or acquired immunodeficiencies, primary infection can be life-threatening, due to rapid dissemination of the virus to various organs [lung, gastrointestinal tract, liver, eye, central nervous system (CNS)]. We retrospectively described and compared the clinical presentations and outcomes of disseminated varicella infection (DV) in patients with acquired (AID) (n= 7) and primary (PID) (n= 12) immunodeficiencies. Patients with AID were on immunosuppression (mostly steroids) for nephrotic syndrome, solid organ transplantation or the treatment of hemopathies, whereas those with PID had combined immunodeficiency (CID) or severe CID (SCID). The course of the disease was severe and fulminant in patients with AID, with multiple organ failure, no rash or a delayed rash, whereas patients with CID and SICD presented typical signs of chickenpox, including a rash, with dissemination to other organs, including the lungs and CNS. In the PID group, antiviral treatment was prolonged until immune reconstitution after bone marrow transplantation, which was performed in 10/12 patients. Four patients died, and three experienced neurological sequelae. SCID patients had the worst outcome. Our findings highlight substantial differences in the clinical presentation and course of DV between children with AID and PID, suggesting differences in pathophysiology. Prevention, early diagnosis and treatment are required to improve outcome.


Asunto(s)
Síndromes de Inmunodeficiencia , Infección por el Virus de la Varicela-Zóster , Adolescente , Antivirales/uso terapéutico , Niño , Preescolar , Resultado Fatal , Femenino , Humanos , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Lactante , Masculino , Infección por el Virus de la Varicela-Zóster/tratamiento farmacológico
13.
Ann Hum Biol ; 35(2): 185-97, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18428012

RESUMEN

BACKGROUND: Reliable field methods to measure fat mass (FM) in children may contribute to primary prevention of childhood obesity. AIM: The objective was to compare the accuracy of existing field methods (skinfold thickness (SF), leg-to-leg bioelectrical impedance analysis (BIA), anthropometrics for FM measurement in prepubertal European children. SUBJECTS AND METHODS: Reference FM was measured in 55 French children (30 boys, 25 girls; mean age 8.7 years) using a three-compartment model: body volume (BV) was assessed by air displacement plethysmography (ADP) and total body water (TBW) was assessed by deuterium dilution. Agreement between field methods and the reference method was assessed using Bland-Altman analyses. Since field methods for FM measurement are reported to be population-dependent, adjustment to the study population was performed using stepwise multiple linear regressions modelling. RESULTS: Even after adjustment, field methods exhibited a high correlation (R(2) = 0.71-0.84) but a moderate agreement (+/-3.32 to +/-4.47 kg for fat mass) with the reference model. Methods based on BIA or SF performed slightly better than those based on anthropometry. CONCLUSIONS: Field methods for FM measurement may be recommended for epidemiological applications, but not for individual follow-up. New field equipment is required to improve accuracy of FM measurement in children and make individual follow-up possible.


Asunto(s)
Tejido Adiposo/anatomía & histología , Diseño de Investigaciones Epidemiológicas , Antropometría/métodos , Composición Corporal , Tamaño Corporal , Agua Corporal , Niño , Estudios de Cohortes , Deuterio/análisis , Impedancia Eléctrica , Femenino , Francia , Humanos , Masculino , Pletismografía , Valores de Referencia , Grosor de los Pliegues Cutáneos
14.
Pediatr Infect Dis J ; 26(4): 293-9, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17414390

RESUMEN

BACKGROUND: Pertussis vaccination has reduced the number of notified cases in industrialized countries from peak years by more than 95%. The effect of recently recommended adult and adolescent vaccination strategies on infant pertussis depends, in part, on the proportion of infants infected by adults and adolescents. This proportion, however, remains unclear, because studies have not been able to determine the source case for 47%-60% of infant cases. METHODS: A prospective international multicenter study was conducted of laboratory confirmed infant pertussis cases (aged

Asunto(s)
Bordetella pertussis/aislamiento & purificación , Trazado de Contacto , Tos Ferina/transmisión , Adolescente , Adulto , Anciano , Anticuerpos Antibacterianos/sangre , Bordetella pertussis/genética , Bordetella pertussis/inmunología , Niño , Preescolar , Humanos , Lactante , Persona de Mediana Edad , Padres , Reacción en Cadena de la Polimerasa , Hermanos , Tos Ferina/diagnóstico , Tos Ferina/microbiología , Tos Ferina/patología
15.
Rev Prat ; 57(17): 1912-8, 2007 Nov 15.
Artículo en Francés | MEDLINE | ID: mdl-18095628

RESUMEN

Acute respiratory tract infections are the main cause of morbidity and mortality in infants and young children. They are the first cause of hospitalisation in industrialised countries. A safe and efficient antiVRS vaccine would be a very important advance but, unfortunately, it does not exist at this moment. Recommendations of the influenza vaccine could be extended, as it is the case in USA, to decrease infants hospitalisations who are under one year of age and to decrease acute respiratory tract infections in children and adults. Theses vaccines are susceptible to play a role in coinfections and bacterial super infections. Haemophilus influenzae conjugate vaccine is very efficient against pneumonia due to this bacteria. Heptavalent pneumococcal conjugate vaccine decreases the number of otitis media and particularly recidivant and complicated otitis media. This vaccine decreases the number of pneumonia and hospitalizations for pneumonia in U.S.A. This vaccine acts on the carriage of pneumococcal strains and plays a role in decreasing antibiotic resistance. Epidemiological surveillance of pneumococcal strains is necessary because of a possible selection of strains due to the vaccine.


Asunto(s)
Infecciones del Sistema Respiratorio/prevención & control , Enfermedad Aguda , Vacunas Bacterianas/uso terapéutico , Niño , Humanos , Vacunas Virales/uso terapéutico
17.
Rev Prat ; 57(16): 1767-73, 2007 Oct 31.
Artículo en Francés | MEDLINE | ID: mdl-18092719

RESUMEN

Recurrent upper respiratory tract infections should be considered as a normal process in infants who build immune defenses in an environment where they meet viruses. Nasal lavage with saline serum and the blowing when possible are the only treatment justified in all the cases. Antibiotic treatment is not justified. It does not shorten the course and does not prevent complications. Recurrent otitis media (three episodes in six months or four in one year) are the most common complication. Bacterial superinfections are due to bacteria who colonise nasopharynx. Facilitating factors for recurrent ENT infections in children are individual: age, sex, martial deficiency, gastro-oesophageal reflux, adenoid growths. Other facilitating factors are environmental: absence or short duration of breast-feading, pollution, passive smoking, day care center. In the great majority of cases, laboratory tests are unnecessary. The most important is to reassure because recurrent upper respiratory infections improve with time. Different facilitating factors previously described have to be taken into account and should allow to decrease the number of episodes.


Asunto(s)
Otitis Media/fisiopatología , Infecciones del Sistema Respiratorio/fisiopatología , Tonsila Faríngea/patología , Factores de Edad , Contaminación del Aire/efectos adversos , Lactancia Materna , Preescolar , Femenino , Reflujo Gastroesofágico/complicaciones , Humanos , Hipersensibilidad/complicaciones , Hipertrofia , Lactante , Masculino , Chupetes , Faringitis/fisiopatología , Recurrencia , Rinitis/fisiopatología , Factores de Riesgo , Factores Sexuales
18.
Pediatr Infect Dis J ; 25(10): 930-2, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17006289

RESUMEN

BACKGROUND: The only available data about tuberculosis (TB) among adolescents date back to the 1980s, although the incidence of tuberculosis has been increasing in this age group. METHODS: Medical records were reviewed for all adolescents aged 12 to 18 years hospitalized with the diagnosis of TB in Avicenne/Jean Verdier Teaching hospital (Seine-Saint-Denis, suburb of Paris) between September 2000 and December 2004. RESULTS: Of the 52 patients identified, 52% were female. Median age at diagnosis was 15 years (range, 12-18 years). The proportion of adolescents known to be born abroad was 90%. Diagnoses resulted from the examination of a sick child in 79% of cases, a case contact investigation of an adult suspected of having TB in 19% and routine tuberculin skin test in 2%. Twenty-seven of 52 patients (52%) had isolated pulmonary disease. Sixteen patients (31%) had pulmonary and extrapulmonary TB and 8 cases (17%) had exclusively extrapulmonary disease. The site of extrapulmonary TB included pleural (n = 8), meningitis (n = 4), lymph node (n = 4), peritoneal (n = 5), osteoarticular (n = 3) and genitourinary (n = 1). TB was confirmed by the isolation of Mycobacterium tuberculosis from sputum (n = 21), gastric aspirate (n = 8), bone (n = 1) or cerebrospinal fluid (n = 2). No case had a relapse or recurrence of disease in median 3.2 years of follow up. CONCLUSIONS: Our results indicate that demographic and clinical characteristics of adolescents with TB differed from adults and children. A specific approach to the prevention and treatment of TB in adolescents is absolutely necessary.


Asunto(s)
Mycobacterium tuberculosis/aislamiento & purificación , Tuberculosis/epidemiología , Adolescente , Huesos/microbiología , Líquido Cefalorraquídeo/microbiología , Trazado de Contacto , Femenino , Francia , Jugo Gástrico/microbiología , Lavado Gástrico , Hospitales de Enseñanza , Humanos , Incidencia , Masculino , Características de la Residencia , Estudios Retrospectivos , Esputo/microbiología , Prueba de Tuberculina , Tuberculosis/complicaciones , Tuberculosis/fisiopatología
20.
J Infect Public Health ; 9(3): 339-47, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26688376

RESUMEN

Invasive meningococcal disease (IMD) is life-threatening and can result in severe sequelae. In France, no data have been published on the costs of severe IMD cases. Two realistic scenarios were developed with national experts (clinicians and social workers): a 6-year-old child with purpura fulminans with amputation of both legs below the knee (case A) and a 3-year-old with meningitis and severe neurological sequelae (case B). Additional scenarios included other typical sequelae of IMD such as chronic kidney disease (CKD), profound deafness and epilepsy. Data on healthcare, disability, educational and other resource use were obtained from experts and families of patients with similar sequelae. Unit costs (2013) were mainly obtained from the literature and the National Health Insurance (NHI). Time horizon was based on life expectancies of patients (77 and 55 years, respectively). A 4% discount rate decreasing to 2% after 30 years was applied. Costs are presented from the perspective of the NHI, publicly funded organizations and patients' families or their private health insurances. purpura fulminans with amputations is associated with a lifelong discounted cost of €768,875. Adding CKD doubles the amount (€1,480,545). Meningitis with severe neuro-cognitive sequelae results in a lifelong discounted cost of €1,924,475. Adding profound deafness and epilepsy slightly increases the total cost (€2,267,251). The first year is the most expensive in both scenarios (€166,890 and €160,647 respectively). The main cost drivers for each scenario are prostheses and child/adult stays in healthcare facilities, respectively. Overall, patients' families or his private insurance had to pay around 13% of total cost (101,833€ and 258,817€, respectively). This study fills a gap in the body of knowledge on IMD sequelae care and lifetime costs in France. The potentially high economic burden of IMD, in addition to its physical, psychological and social burden, reinforces the need for prevention.


Asunto(s)
Costo de Enfermedad , Meningitis Meningocócica/complicaciones , Meningitis Meningocócica/economía , Púrpura Fulminante/complicaciones , Púrpura Fulminante/economía , Sepsis/complicaciones , Sepsis/economía , Amputación Quirúrgica , Niño , Preescolar , Femenino , Francia , Humanos , Masculino , Trastornos Mentales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA